We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss
Read MoreHide Full Article
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) incurred second-quarter 2017 loss of 29 cents per share (including the impact of stock-based compensation), wider than the Zacks Consensus Estimate loss of 28 cents and the year-ago loss of 2 cents. Higher costs and soft revenues hurt earnings in the quarter.
Revenues rose 1.9% year over year to $70.9 million and missed the Zacks Consensus Estimate of $74 million. Revenues were below estimates as higher Exparel revenues were offset by lower other product and collaboration revenues. However, the company remains encouraged by the progress of its Johnson & Johnson (JNJ - Free Report) partnership to co-promote Exparel (entered into in Jan 2017), with their sales and medical education teams actively supporting Exparel in the orthopedic space.
Pacira’s share price has increased 18.8% year to date, compared with the Zacks classified industry’s gain of 1.7%.
Quarter in Detail
Pacira’s top line comprises product revenues, collaborative licensing and milestone revenues, and royalty revenues. Exparel, generated revenues of $69.8 million, up 6.1% year over year, but DepoCyt(e) and other product revenues came in at $0.4 million, down 81.1%.
Collaborative licensing and milestone revenues were down 90.4% to $0.1 million. Royalty revenues were $0.7 million, up 11.4%.
Research and development (R&D) expenses ((including the impact of stock-based compensation)were up 101.4% to $18.9 million, while selling, general and administrative (SG&A) expenses increased 9.4% to $39.6 million.
Recent Developments
The company remains on track to resubmit its supplemental new drug application, (sNDA), to the FDA later in 2017, seeking expansion of the EXPAREL label to include the indication of administration via nerve block.The sNDA will be based on two pivotal efficacy studies. The company believes that the data from these two studies will meet the requirements of the FDA as stated in the complete response letter (issued in Mar 2015).
Pacira is also evaluation Exparel for the treatment of total knee arthroplasty (TKA). In Mar 2017, the company announced positive topline data from the this Phase IV study. The study met its co-primary endpoints for postsurgical pain and opioid reduction against an active comparator- bupivacaine. The Exparel group achieved a statistically significant reduction in under the curve (AUC) of visual analog scale (VAS) scores compared to those who did not receive Exparel.
2017 Outlook
Pacira reiterated its guidance for 2017. It projects Exparel sales in the range of $290 million to $310 million. R&D expenses (excluding stock-based compensation) are expected in the band of $50 million to $60 million. SG&A expenses (excluding stock based compensation are anticipated to be in $145–$155 million range.Also, stock-based compensation is expected to be in the range of $30 -$35 million.
Pacira Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Exelixis’ pulled off positive earnings surprises in all the trailing four quarters, with an average beat of 512.11%. The share price of the company has increased 78.6% year to date.
Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 60 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 59.6% year to date.
More Stock News: Tech Opportunity Worth $386 Billion in 2017 From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) incurred second-quarter 2017 loss of 29 cents per share (including the impact of stock-based compensation), wider than the Zacks Consensus Estimate loss of 28 cents and the year-ago loss of 2 cents. Higher costs and soft revenues hurt earnings in the quarter.
Revenues rose 1.9% year over year to $70.9 million and missed the Zacks Consensus Estimate of $74 million. Revenues were below estimates as higher Exparel revenues were offset by lower other product and collaboration revenues. However, the company remains encouraged by the progress of its Johnson & Johnson (JNJ - Free Report) partnership to co-promote Exparel (entered into in Jan 2017), with their sales and medical education teams actively supporting Exparel in the orthopedic space.
Pacira’s share price has increased 18.8% year to date, compared with the Zacks classified industry’s gain of 1.7%.
Quarter in Detail
Pacira’s top line comprises product revenues, collaborative licensing and milestone revenues, and royalty revenues. Exparel, generated revenues of $69.8 million, up 6.1% year over year, but DepoCyt(e) and other product revenues came in at $0.4 million, down 81.1%.
Collaborative licensing and milestone revenues were down 90.4% to $0.1 million. Royalty revenues were $0.7 million, up 11.4%.
Research and development (R&D) expenses ((including the impact of stock-based compensation)were up 101.4% to $18.9 million, while selling, general and administrative (SG&A) expenses increased 9.4% to $39.6 million.
Recent Developments
The company remains on track to resubmit its supplemental new drug application, (sNDA), to the FDA later in 2017, seeking expansion of the EXPAREL label to include the indication of administration via nerve block.The sNDA will be based on two pivotal efficacy studies. The company believes that the data from these two studies will meet the requirements of the FDA as stated in the complete response letter (issued in Mar 2015).
Pacira is also evaluation Exparel for the treatment of total knee arthroplasty (TKA). In Mar 2017, the company announced positive topline data from the this Phase IV study. The study met its co-primary endpoints for postsurgical pain and opioid reduction against an active comparator- bupivacaine. The Exparel group achieved a statistically significant reduction in under the curve (AUC) of visual analog scale (VAS) scores compared to those who did not receive Exparel.
2017 Outlook
Pacira reiterated its guidance for 2017. It projects Exparel sales in the range of $290 million to $310 million. R&D expenses (excluding stock-based compensation) are expected in the band of $50 million to $60 million. SG&A expenses (excluding stock based compensation are anticipated to be in $145–$155 million range.Also, stock-based compensation is expected to be in the range of $30 -$35 million.
Pacira Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Pacira Pharmaceuticals, Inc. Price, Consensus and EPS Surprise | Pacira Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Pacira currently carries a Zacks Rank #4 (Sell). Better-ranked pharma stocks in the same space include Exelixis, Inc. (EXEL - Free Report) and Enzo Biochem, Inc. (ENZ - Free Report) . Both Exelixis and Enzo Biochem sport a Zacks Rank#2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Exelixis’ pulled off positive earnings surprises in all the trailing four quarters, with an average beat of 512.11%. The share price of the company has increased 78.6% year to date.
Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 60 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 59.6% year to date.
More Stock News: Tech Opportunity Worth $386 Billion in 2017 From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>